Research & Literature

Immune reconstitution inflammatory syndrome in HIV-infected patients.

Walker NF, Scriven J, Meintjes G, Wilkinson RJ

HIV/AIDS (Auckland, N.Z.) 2015; (7()):49-64 doi:10.2147/HIV.S42328.

Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review.

Manzardo C, Guardo AC, Letang E, et al.

Expert review of anti-infective therapy 2015; (13(6)):751-67 doi:10.1586/14787210.2015.1029917.

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Crooks AM, Bateson R, Cope AB, et al.

The Journal of infectious diseases 2015; (212(9)):1361-5 doi:10.1093/infdis/jiv218.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Sax PE, Wohl D, Yin MT, et al.

Lancet (London, England) 2015; (385(9987)):2606-15.

Geriatric Syndromes in Older HIV-Infected Adults.

Greene M, Covinsky KE, Valcour V, et al.

Journal of acquired immune deficiency syndromes (1999) 2015; (69(2)):161-7 doi:10.1097/QAI.0000000000000556.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

, Lundgren JD, Babiker AG, et al.

The New England journal of medicine 2015; (373(9)):795-807 doi:10.1056/NEJMoa1506816.

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

, Danel C, Moh R, et al.

The New England journal of medicine 2015; (373(9)):808-22 doi:10.1056/NEJMoa1507198.

Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.

Sidhu VK, Foisy MM, Hughes CA

The Annals of pharmacotherapy 2015; (49(12)):1343-8 doi:10.1177/1060028015605113.

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Martin-Iguacel R, Llibre JM, Friis-Moller N

Current HIV/AIDS reports 2015; (12(4)):375-87 doi:10.1007/s11904-015-0284-6.

Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.

Hou P, Chen S, Wang S, et al.

Scientific reports 2015; (5()):15577 doi:10.1038/srep15577.

HIV-Associated TB Syndemic: A Growing Clinical Challenge Worldwide.

Montales MT, Chaudhury A, Beebe A, et al.

Frontiers in public health 2015; (3()):281 doi:10.3389/fpubh.2015.00281.

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.

Achhra AC, Nugent M, Mocroft A, et al.

Current HIV/AIDS reports 2016; (13(3)):149-57 doi:10.1007/s11904-016-0315-y.

Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV.

Martin-Iguacel R, Negredo E, Peck R, Friis-Møller N

Current hypertension reports 2016; (18(6)):46 doi:10.1007/s11906-016-0656-3.

A severe hypersensitivity reaction to abacavir following re-challenge.

Todd S, Emerson CR

International journal of STD & AIDS 2017; (28(3)):310-311 doi:10.1177/0956462416665937.

Cytokines and T-Cell Homeostasis in HIV Infection.

Freeman ML, Shive CL, Nguyen TP, et al.

The Journal of infectious diseases 2016; (214 Suppl 2()):S51-7 doi:10.1093/infdis/jiw287.

Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.

Sereti I, Krebs SJ, Phanuphak N, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; (64(2)):124-131 doi:10.1093/cid/ciw683.

The evolving role of CD4 cell counts in HIV care.

Ford N, Meintjes G, Vitoria M, et al.

Current opinion in HIV and AIDS 2017; (12(2)):123-128 doi:10.1097/COH.0000000000000348.

The Immune Interaction between HIV-1 Infection and Mycobacterium tuberculosis.

Du Bruyn E, Wilkinson RJ

Microbiology spectrum 2016; (4(6)) doi:10.1128/microbiolspec.TBTB2-0012-2016.

Tuberculosis Associated with HIV Infection.

Tornheim JA, Dooley KE

Microbiology spectrum 2017; (5(1)) doi:10.1128/microbiolspec.TNMI7-0028-2016.

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

Piroth L, Wittkop L, Lacombe K, et al.

Journal of hepatology 2017; (67(1)):23-31 doi:10.1016/j.jhep.2017.02.012.

Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir.

Bui JK, Sobolewski MD, Keele BF, et al.

PLoS pathogens 2017; (13(3)):e1006283 doi:10.1371/journal.ppat.1006283.

Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.

Gotham D, Hill A, Pozniak AL

Current opinion in HIV and AIDS 2017; (12(4)):324-333 doi:10.1097/COH.0000000000000379.

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.

The lancet. HIV 2017; (4(8)):e349-e356 doi:10.1016/S2352-3018(17)30066-8.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Sax PE, Pozniak A, Montes ML, et al.

Lancet (London, England) 2017; (390(10107)):2073-2082 doi:10.1016/S0140-6736(17)32340-1.

Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection.

Shan L, Deng K, Gao H, et al.

Immunity 2017; (47(4)):766-775.e3 doi:10.1016/j.immuni.2017.09.014.

Benefits and risks of rapid initiation of antiretroviral therapy.

Ford N, Migone C, Calmy A, et al.

AIDS (London, England) 2018; (32(1)):17-23 doi:10.1097/QAD.0000000000001671.

Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.

Hermans LE, Moorhouse M, Carmona S, et al.

The Lancet. Infectious diseases 2018; (18(2)):188-197 doi:10.1016/S1473-3099(17)30681-3.

HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.

Yukl SA, Kaiser P, Kim P, et al.

Science translational medicine 2018; (10(430)) doi:10.1126/scitranslmed.aap9927.

Clinical features of acute human immunodeficiency virus infection in Taiwan: A multicenter study.

Lin TY, Yang CJ, Liu CE, et al.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2019; (52(5)):700-709 doi:10.1016/j.jmii.2018.01.005.

Central nervous system infection with Toxoplasma gondii.

Marra CM

Handbook of clinical neurology 2018; (152()):117-122 doi:10.1016/B978-0-444-63849-6.00009-8.

Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings.

Waitt C, Low N, Van de Perre P, et al.

The lancet. HIV 2018; (5(9)):e531-e536 doi:10.1016/S2352-3018(18)30098-5.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Saag MS, Benson CA, Gandhi RT, et al.

JAMA 2018; (320(4)):379-396 doi:10.1001/jama.2018.8431.

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Calvez V, Paredes R, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019; (68(2)):177-187 doi:10.1093/cid/ciy463.

The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research.

Walker NF, Stek C, Wasserman S, et al.

Current opinion in HIV and AIDS 2018; (13(6)):512-521 doi:10.1097/COH.0000000000000502.

Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review.

LeMessurier J, Traversy G, Varsaneux O, et al.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2018; (190(46)):E1350-E1360 doi:10.1503/cmaj.180311.

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study.

Mounzer K, Hsu R, Fusco JS, et al.

AIDS research and therapy 2019; (16(1)):1 doi:10.1186/s12981-019-0217-3.

Kinetics of Early Innate Immune Activation during HIV-1 Infection of Humanized Mice.

Skelton JK, Ortega-Prieto AM, Kaye S, et al.

Journal of virology 2019; (93(11)) doi:10.1128/JVI.02123-18.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, et al.

Lancet (London, England) 2019; (393(10189)):2428-2438 doi:10.1016/S0140-6736(19)30418-0.

The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.

Sharma S, Schlusser KE, de la Torre P, et al.

AIDS (London, England) 2019; (33(8)):1335-1344 doi:10.1097/QAD.0000000000002219.

Rapid initiation of antiretroviral therapy for people living with HIV.

Mateo-Urdiales A, Johnson S, Smith R, et al.

The Cochrane database of systematic reviews 2019; (6()):CD012962 doi:10.1002/14651858.CD012962.pub2.

Management of active tuberculosis in adults with HIV.

Meintjes G, Brust JCM, Nuttall J, Maartens G

The lancet. HIV 2019; (6(7)):e463-e474 doi:10.1016/S2352-3018(19)30154-7.

Injection Practices and Sexual Behaviors Among Persons with Diagnosed HIV Infection Who Inject Drugs - United States, 2015-2017.

Dasgupta S, Tie Y, Lemons A, et al.

MMWR. Morbidity and mortality weekly report 2019; (68(30)):653-657 doi:10.15585/mmwr.mm6830a1.

Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Engelman AN

The Journal of biological chemistry 2019; (294(41)):15137-15157 doi:10.1074/jbc.REV119.006901.

Immune Control of HIV.

Balasubramaniam M, Pandhare J, Dash C

Journal of life sciences (Westlake Village, Calif.) 2019; (1(1)):4-37.

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

Maggiolo F, Rizzardini G, Raffi F, et al.

The lancet. HIV 2019; (6(10)):e655-e666 doi:10.1016/S2352-3018(19)30195-X.

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

Sax PE, Erlandson KM, Lake JE, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (71(6)):1379-1389 doi:10.1093/cid/ciz999.

Women living with HIV in high-income settings and breastfeeding.

Moseholm E, Weis N

Journal of internal medicine 2020; (287(1)):19-31 doi:10.1111/joim.12986.

Tuberculosis-immune reconstitution inflammatory syndrome.

Lanzafame M, Vento S

Journal of clinical tuberculosis and other mycobacterial diseases 2016; (3()):6-9 doi:10.1016/j.jctube.2016.03.002.

Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.

Scott LJ

Drugs 2020; (80(1)):61-72 doi:10.1007/s40265-019-01247-1.

The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala.

Samayoa B, Aguirre L, Bonilla O, et al.

Open forum infectious diseases 2020; (7(1)):ofz534 doi:10.1093/ofid/ofz534.

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.

Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM

HIV medicine 2020; (21 Suppl 1()):3-16 doi:10.1111/hiv.12833.

Decreased Time From Human Immunodeficiency Virus Diagnosis to Care, Antiretroviral Therapy Initiation, and Virologic Suppression during the Citywide RAPID Initiative in San Francisco.

Bacon O, Chin J, Cohen SE, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(1)):e122-e128 doi:10.1093/cid/ciaa620.

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

Orkin C, DeJesus E, Sax PE, et al.

The lancet. HIV 2020; (7(6)):e389-e400 doi:10.1016/S2352-3018(20)30099-0.

Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.

Santevecchi BA, Miller S, Childs-Kean LM

The Annals of pharmacotherapy 2020; (54(12)):1252-1259 doi:10.1177/1060028020933772.

Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016.

Marcus JL, Leyden WA, Alexeeff SE, et al.

JAMA network open 2020; (3(6)):e207954 doi:10.1001/jamanetworkopen.2020.7954.

The multifaceted nature of HIV latency.

Dufour C, Gantner P, Fromentin R, Chomont N

The Journal of clinical investigation 2020; (130(7)):3381-3390.

Human Immunodeficiency Virus Prevention for People Who Use Drugs: Overview of Reviews and the ICOS of PICOS.

Johnson WD, Rivadeneira N, Adegbite AH, et al.

The Journal of infectious diseases 2020; (222(Suppl 5)):S278-S300 doi:10.1093/infdis/jiaa008.

Managing HIV-associated inflammation and ageing in the era of modern ART.

Bloch M, John M, Smith D, et al.

HIV medicine 2020; (21 Suppl 3()):2-16 doi:10.1111/hiv.12952.

New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.

Dunn D, Price H, Vudriko T, et al.

Journal of acquired immune deficiency syndromes (1999) 2021; (86(1)):98-103 doi:10.1097/QAI.0000000000002517.

A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

Webel AR, Schexnayder J, Cioe PA, Zuñiga JA

The Journal of the Association of Nurses in AIDS Care : JANAC 2021; (32(3)):322-346 doi:10.1097/JNC.0000000000000240.

Integrase strand transfer inhibitor treatment does not increase the incidence of immune reconstitution inflammatory syndrome in HIV-infected Koreans.

Kim J, Nam HJ, Kang SJ, et al.

HIV medicine 2021; (22(8)):705-714 doi:10.1111/hiv.13117.

No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.

Atkinson A, Miro JM, Mocroft A, et al.

Journal of the International AIDS Society 2021; (24(6)):e25726 doi:10.1002/jia2.25726.

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.

Gaur AH, Cotton MF, Rodriguez CA, et al.

The Lancet. Child & adolescent health 2021; (5(9)):642-651 doi:10.1016/S2352-4642(21)00165-6.

The Hitchhiker Guide to CD4+ T-Cell Depletion in Lentiviral Infection. A Critical Review of the Dynamics of the CD4+ T Cells in SIV and HIV Infection.

Le Hingrat Q, Sereti I, Landay AL, et al.

Frontiers in immunology 2021; (12()):695674 doi:10.3389/fimmu.2021.695674.

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.

Poizot-Martin I, Brégigeon S, Palich R, et al.

Cancers 2022; (14(4)) doi:10.3390/cancers14040986.

Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies.

Singh AK, Das K

Viruses 2022; (14(5)) doi:10.3390/v14051027.

HIV nucleoside reverse transcriptase inhibitors.

Amblard F, Patel D, Michailidis E, et al.

European journal of medicinal chemistry 2022; (240()):114554 doi:10.1016/j.ejmech.2022.114554.

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.

Malaba TR, Nakatudde I, Kintu K, et al.

The lancet. HIV 2022; (9(8)):e534-e543 doi:10.1016/S2352-3018(22)00173-4.

A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch.

Hermans LE, Ter Heine R, Schuurman R, et al.

AIDS (London, England) 2022; (36(14)):1959-1968 doi:10.1097/QAD.0000000000003349.

Same-day and rapid initiation of antiretroviral therapy in people living with HIV in Asia. How far have we come?

Hung CC, Phanuphak N, Wong CS, et al.

HIV medicine 2022; (23 Suppl 4()):3-14 doi:10.1111/hiv.13410.

Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.

Burgos J, Moreno-Fornés S, Reyes-Urueña J, et al.

The Journal of antimicrobial chemotherapy 2022; (78(1)):108-116 doi:10.1093/jac/dkac361.

Seroprevalence and effect of HBV and HCV co-infections on the immuno-virologic responses of adult HIV-infected persons on anti-retroviral therapy.

Annison L, Hackman H, Eshun PF, et al.

PloS one 2022; (17(11)):e0278037 doi:10.1371/journal.pone.0278037.

Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.

de Salazar A, Viñuela L, Fuentes A, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023; (76(9)):1628-1635 doi:10.1093/cid/ciac972.

Frailty and Aging in HIV- Status Post 13 Years of National Awareness.

Eke UA, Mohanty K, Gruber-Baldini AL, Ryan AS

The Journal of frailty & aging 2023; (12(1)):49-58 doi:10.14283/jfa.2022.45.

Modelling the impact of CD4 testing on mortality from TB and cryptococcal meningitis among patients with advanced HIV disease in nine countries.

Oboho IK, Paulin H, Corcoran C, et al.

Journal of the International AIDS Society 2023; (26(3)):e26070 doi:10.1002/jia2.26070.

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.

Rolle CP, Berhe M, Singh T, et al.

Open forum infectious diseases 2023; (10(3)):ofad101 doi:10.1093/ofid/ofad101.

Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis.

Valenzuela-Rodriguez G, Diaz-Arocutipa C, Collins JA, Hernandez AV

Journal of clinical medicine 2023; (12(11)) doi:10.3390/jcm12113644.

Role of viral suppression in HIV treatment and prevention and its potential in addressing harmful laws and discrimination.

Seale A, Baggaley R, Vojnov L, Doherty M

Sexual health 2023; (20(3)):181-185 doi:10.1071/SH23048.

The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review.

Broyles LN, Luo R, Boeras D, Vojnov L

Lancet (London, England) 2023; (402(10400)):464-471 doi:10.1016/S0140-6736(23)00877-2.

Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.

Duggan NN, Dragic T, Chanda SK, Pache L

Viruses 2023; (15(12)) doi:10.3390/v15122435.

2023 updated guidelines on infant feeding and HIV in the United States: what are they and why have recommendations changed.

Pollock L, Levison J

Topics in antiviral medicine 2023; (31(5)):576-586.

Risk of sexual transmission of HIV in the context of viral load suppression.

Djiadeu P, Begum H, Sabourin S, et al.

Canada communicable disease report = Releve des maladies transmissibles au Canada 2023; (49(11-12)):457-464 doi:10.14745/ccdr.v49i1112a01.

Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.

Prosty C, Katergi K, Sorin M, et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024; (30(7)):866-876 doi:10.1016/j.cmi.2024.03.037.

Late presentations and missed opportunities among newly diagnosed HIV patients presenting to a specialty clinic in Lebanon.

Mahmoud M, Ballouz T, Lahoud C, et al.

Scientific reports 2024; (14(1)):8296 doi:10.1038/s41598-024-55277-1.

Cardiometabolic health in people with HIV: expert consensus review.

Batterham RL, Bedimo RJ, Diaz RS, et al.

The Journal of antimicrobial chemotherapy 2024; (79(6)):1218-1233 doi:10.1093/jac/dkae116.

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis.

Yoo JJ, Jung EA, Kim SG, et al.

Journal of the International AIDS Society 2024; (27(9)):e26358 doi:10.1002/jia2.26358.

Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.

Short WR, Patel P, Verdier G, et al.

Infectious diseases and therapy 2025; (14(1)):59-80 doi:10.1007/s40121-024-01085-z.

Pneumocystis Pneumonia-Is it Still a Threat Among People With Human Immunodeficiency Virus (HIV)? A Danish HIV Cohort Study.

Møller AK, Schnoor SB, Petersen I, et al.

Open forum infectious diseases 2025; (12(6)):ofaf289 doi:10.1093/ofid/ofaf289.

Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis.

Dugdale CM, Ufio O, Giardina J, et al.

Lancet (London, England) 2025; (406(10501)):349-357 doi:10.1016/S0140-6736(25)00765-2.

Suboptimal ART adherence, undetectable urine tenofovir, and higher C-reactive protein values.

Ghanooni D, Heise MJ, Sassaman K, et al.

AIDS (London, England) 2025; (39(13)):1975-1978 doi:10.1097/QAD.0000000000004288.

High-level multi-class transmitted antiretroviral resistance in a man with newly acquired HIV.

Miller TR, Gruta C, Sison R, Fierer DS

International journal of STD & AIDS 2026; (37(3)):319-322 doi:10.1177/09564624251396374.

Evaluation of tenofovir alafenamide- versus tenofovir disoproxil fumarate-containing regimens on renal outcomes: systematic literature review and meta-analysis.

Liang X, Park KY, Lee H, et al.

BMC nephrology 2025; doi:10.1186/s12882-025-04628-9.

The interplay of comorbidity, disability, and physical activity among older adults living with HIV: insights from the CHANGE HIV study.

Su TT, O'Brien KK, Zhabokritsky A, et al.

BMC geriatrics 2026; (26(1)):159 doi:10.1186/s12877-025-06939-w.

The role of pyroptosis during HIV infection.

Yaseen MM, Abuharfeil NM, Darmani H, Shatnawi MN

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026; (75(1)):12 doi:10.1007/s00011-025-02164-8.

The impact of HIV-1 Nef on CD4+ T cells.

Yaseen MM, Abuharfeil NM, Darmani H

Critical reviews in biochemistry and molecular biology 2026; (61(1-3)):24-54 doi:10.1080/10409238.2025.2599773.

A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).

Koethe JR, Lake JE, Kantor A, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026; (83(1)):e81-e89 doi:10.1093/cid/ciag196.

International guidelines for the management of healthcare workers living with HIV: a systematic comparative review.

Diel R, Nienhaus A

GMS hygiene and infection control 2026; (21()):Doc34 doi:10.3205/dgkh000643.

Non-integrase mechanisms for dolutegravir resistance.

Engelman AN

Retrovirology 2026; (23(1)).

Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review.

Cossu MV, Matone M, Iannone V, et al.

Frontiers in reproductive health 2026; (8()):1805648 doi:10.3389/frph.2026.1805648.

Seroprevalence and Early Indicators of HBV and HCV Co-infection Among Newly Diagnosed HIV Patients: A Cross-Sectional Study from India.

Khan NH, Kumar SN, Singh V, et al.

AIDS and behavior 2026; doi:10.1007/s10461-026-05251-x.

Analysis of HIV Drug Resistance Mutations Along With Treatment Outcomes of Efavirenz-Based Regimens in Patients With V179D/E Mutations in Guangzhou, China.

Zheng X, Xiao Y, Zhang Y, et al.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale 2026; (2026()):2598894 doi:10.1155/cjid/2598894.

Association of Prior SARS-CoV-2 Infection with Immune Activation in Virally Suppressed People Living with HIV.

Suba MI, Rosca O, Hogea B, et al.

Microorganisms 2026; (14(8)) doi:10.3390/microorganisms14081624.

Hematological Profile and Outcomes in Newly Diagnosed Patients with HIV: A 12-Month Single-Centre Cohort Study.

Padurariu-Covit MD, Miulescu M, Bogdan PM, et al.

Viruses 2026; (18(8)) doi:10.3390/v18080831.